apy and cytoreductive nephrectomy utilization. Urol. 2015;85:442-451.
8.Conti SL, Thomas IC, Hagedorn JC, et al. Utilization of cytoreductive
nephrectomy and patient survival in the he targeted therapy era. Int J
Cancer. 2014;134:22445-2252.
9. Tsao CK, Small AC, Kates M, et al. Cytoreductive nephrectomy for
metastatic renal cell carcinoma in the era of targeted therapy in the
United States: a SEER analysis. World J Urol. 2013;31:1535-1539.
10. Petrelli F, Coinu A, Vavassori I, et al: Cytoreductive nephrectomy in
metastatic renal cell carcinoma treated with targeted therapies: A systematic
review with a meta-analysis. Clin Genitourin Cancer. epub ahead
of print on April 8, 2016
11. Choueiri TK, Xie W, Kollmannsberger C, et al: The impact of cytoreductive
nephrectomy on survival of patients with metastatic renal
cell carcinoma receiving vascular endothelial growth factor targeted
therapy. J Urol. 185:60-66, 2011
12. Heng DY, Wells JC, Rini BI, et al: Cytoreductive nephrectomy in patients
with synchronous metastases from renal cell carcinoma: Results
from the International Metastatic Renal Cell Carcinoma Database Consortium.
Eur Urol. 66: 704-710, 2014
13. Xiao WJ, Zhu Y, Dai B, et al: Assessment of survival of patients with
metastatic clear cell renal cell carcinoma after radical cytoreductive
nephrectomy versus no surgery: A SEER analysis. Int Braz J Urol. 41:288-
295, 2015
14. Abern MR, Scosyrev E, Tsivian M, et al: Survival of patients undergoing
cytoreductive surgery for metastatic renal cell carcinoma in the
targeted-therapy era. Anticancer Res. 34:2405-2411, 2014
15. Zini L, Capitanio U, Perrotte P, et al: Population-based assessment of
survival after cytoreductive nephrectomy versus no surgery in patients
with metastatic renal cell carcinoma. Urology. 73:342-346, 2009
16. Pal SK, SR, Li N, et al. Real-world survival outcomes and prognostic
factors among patients receiving first targeted therapyfor advanced renal
cell carcinoma: a SEER-Medicare Database Analysis. Clin Genitourin Cancer.
2017;144:e573-e582.
17. Heng DY, Wells JC, Rini BI, et al. Cytoreductive nephrectomy in patients
with synchronous metastases from renal cell carcinoma: results
from the International Metastatic Renal Cell Carcinoma Database consortium.
Eur Urol. 2014;666:704-710.
18. Flanigan RC, Salmon SE, Blumenstein BA, et al. For compared with
interferon-alfa-2b alone for metastatic renal-cell cancer. N Engl J Med.
2001;345:1655-1659.
60 Kidney Cancer Journal
19. Mikisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus
interferon-alfa-based immunotherapy compared with interferon alfa
alone in metastatic renal cell carcinoma: a randomized trial. Lancet.
2001;358:9666-970.
20. Motzer RJ, Bukowski RM, Figlin RA, et al. Prognostic nomogram for
sunitinib in patients with metastatic renal cell carcinoma. Cancer.
2008;113:1552-1558.
21.Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification
of 670 patients with advanced renal cell carcinoma. J Clin
Oncol.1999;17:2530-2540.
22. Leibovich BC, Cheville JC, Lohse CM, et al. A scoring algorithm to
predict survival for patients with metastatic clear cell renal cell carcinoma:
a stratification tool for prospective clinical trials. J Urol.
2005;174:1759-1763.
23.Bamias A, Tzannis K, Papatsoris A, et al. Prognostic significance of cytoreductive
nephrectomy in patients with synchronous metastases from
renal cell carcinoma treated with first-line sunitinib: a European multiinstitutional
study. Clin Genitourin Cancer. 2014;12:373-383.
24.Choureiri TK, Motzer RJ. Systemic therapy for metastatic renal-cell
carcinoma. N Engl J Med. 2017;376:354-366.
25. Choueiri TK, Xie W, Kollmannsberger C, et al. The impact of cytoreductive
nephrectomy on survival of patients with metastatic renal
cell carcinoma receiving vascular endothelial growth factor targeted
therapy. J Urol. 2011;185:60.
26. Bex A, Mulders P, Jewett MAS, et al. Immediate versus deferred cytoreductive
nephrectomy (CN) in patients with synchronous metastatic
renal cell carcinoma (mRCC) receiving sunitinib (EORTC 30073
SURTIME). Ann Oncol. 2017; 28: v605.
27. Macleod LC, Odisho AY, Tykodi SS, et al. Comparative Effectiveness
of Initial Surgyer Versus Initial Systemic Therapy for Metastatic Kidney
Cancer in the Targeted Therapy Era: Analysis of a Population-Based Cohort.
Urology. 2018;113:146-152.
28. Bindhi B, Habermann EB, Mason RJ, et al. Comparative survival following
initial cytoreductive nephrectomy versus initial targeted therapy
for metastatic renal cell carcinoma. J Urol. 2018; doi:10.1016/j.juro.
2018.03.077 (Epub ahead of print). KCJ